U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. ALTUVIIIO
  1. Vaccines, Blood & Biologics

ALTUVIIIO

STN: 125771
Proper Name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl
Tradename: ALTUVIIIO
Manufacturer: Bioverativ Therapeutics Inc., a Sanofi Company
Indication:

For use in adults and children with hemophilia A (congenital factor VIII deficiency) for:

  1. Routine prophylaxis to reduce the frequency of bleeding episodes; 
  2. On-demand treatment and control of bleeding episodes; and 
  3. Perioperative management of bleeding.

Product Information

Supporting Documents

 

Back to Top